Clinical Report: DOACs may benefit patients at intermediate risk of AF
Overview
Direct oral anticoagulants (DOACs) may reduce composite clinical events compared to no anticoagulation in patients with atrial fibrillation (AF) at intermediate stroke risk. In a trial involving 1,803 patients, fewer adverse outcomes were observed in the DOAC group over 24 months.
Background
Atrial fibrillation is a significant risk factor for stroke, and managing anticoagulation in patients at intermediate risk is crucial. Current guidelines recommend anticoagulation for patients with a CHA₂DS₂-VASc score of 1 in men and 2 in women, yet the efficacy of DOACs in this specific population has not been extensively studied.
Data Highlights
| Outcome | DOAC Group (n=902) | No Anticoagulation Group (n=901) |
|---|---|---|
| Composite Outcome Events | 4 | 13 |
| Stroke | 3 | 10 |
| Major Bleeding | 3 | 4 |
| Systemic Embolism | 0 | 1 |
| Cardiovascular Mortality | 0 | 0 |
| Clinically Relevant Nonmajor Bleeding | 22 | 14 |
Key Findings
- DOACs were associated with fewer composite clinical events compared to no anticoagulation.
- Only 4 primary outcome events occurred in the DOAC group versus 13 in the no anticoagulation group.
- Stroke incidence was lower in the DOAC group (3 patients) compared to the no anticoagulation group (10 patients).
- Major bleeding rates were similar between groups (3 in DOAC vs. 4 in no anticoagulation).
- Subgroup analyses indicated consistent results across various demographics, though not adjusted for multiple comparisons.
- Limitations included a lower-than-expected number of outcome events and potential biases due to the open-label design.
Clinical Implications
Clinicians should consider the limitations of the study, including the small number of events and potential biases.
Conclusion
The study indicates that DOACs may be advantageous for patients with intermediate-risk atrial fibrillation.
Related Resources & Content
- Daehoon Kim, MD, et al., The New England Journal of Medicine, 2023 -- DOACs may benefit patients at intermediate risk of AF
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation, JACC, 2023
- Efficacy and safety of direct oral anticoagulants for intermediate stroke risk in patients with atrial fibrillation (SINGLE-AF): Study design and protocol, PubMed, 2023
- MDSpire News — DOACs in PE: Need for Risk Stratification
- JAMA Network Open — COX-2–Selective NSAIDs With DOACs in Atrial Fibrillation—Analgesic Safety via Antithrombotic Stewardship
- Clinical Research in Cardiology — Antithrombotic Approaches for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
- ASCO Publications — DOACs vs warfarin: Rethinking anticoagulation strategies for portal vein thrombosis prophylaxis in patients with increased risk.
- DOACs in PE: Need for Risk Stratification
- COX-2–Selective NSAIDs With DOACs in Atrial Fibrillation—Analgesic Safety via Antithrombotic Stewardship
- Antithrombotic Approaches for Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
- 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | JACC
- Efficacy and safety of direct oral anticoagulants for intermediate stroke risk in patients with atrial fibrillation (SINGLE-AF): Study design and protocol.
- Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation | New England Journal of Medicine
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
